The Myeloma Beacon Staff's Archive

The Myeloma Beacon Staff has written 732 article(s) .

[ by | Apr 20, 2015 5:59 pm | 3 Comments ]
Subcutaneous Velcade Leads To Similar Response Rates, But Fewer Side Effects, Compared To IV Velcade In Newly Diagnosed Multiple Myeloma

Initial results of a German clinical trial confirm pre­vi­ous find­ings that sub­cu­ta­ne­ous (under-the-skin) injections of Velcade for the treat­ment of myeloma lead to fewer side effects – but similar overall response rates – com­pared to intra­ve­nous (IV) infusions of the drug.

The trial results also indicate, however, that IV adminis­tra­tion of Velcade may lead to deeper treat­ment responses when patients are given the drug for a limited number of treat­ment cycles.

The German trial is notable not just because it is the …

Tags: , , , , ,
Read the full story »
[ by | Apr 7, 2015 6:43 pm | One Comment ]
Combination Of Farydak And High-Dose Kyprolis Effective In Relapsed Multiple Myeloma

The results of a small Phase 1/2 clinical trial suggest that a com­bi­na­tion of Farydak and high-dose Kyprolis is effective as a treat­ment for relapsed multiple myeloma.

Participants in the trial were heavily pretreated, having had a median of five previous myeloma ther­a­pies. More than 70 per­cent of the patients, however, had at least a partial re­sponse to the trial regi­men at the target doses established during the trial’s first phase. The estimated two-year overall survival rate among the patients …

Tags: , , , , ,
Read the full story »
[ by | Mar 3, 2015 10:36 pm | 8 Comments ]
High-Dose Kyprolis Extends Progression-Free Survival Versus Velcade In Head-To-Head Relapsed Myeloma Trial

Initial results of a large, head-to-head clinical trial show that relapsed myeloma patients treated with high-dose Kyprolis and dex­a­meth­a­sone had twice the progression-free survival of relapsed patients treated with Velcade and dex­a­meth­a­sone.

Median progression-free survival in the Phase 3 trial was 18.7 months in trial participants treated with high-dose Kyprolis (carfilzomib) and dex­a­meth­a­sone (Decadron), compared to 9.4 months in patients treated with Velcade (bor­tez­o­mib) and dex­a­meth­a­sone.

The results of the so-called “ENDEAVOR” trial were announced …

Tags: , , , ,
Read the full story »
[ by | Feb 26, 2015 7:40 pm | 4 Comments ]
Farydak – Questions & Answers About The FDA Approval

The U.S. Food and Drug Administration (FDA) on Monday approved Farydak (panobinostat) for the treatment of multiple myeloma (see related Beacon news).

Since the FDA announced its decision, multiple myeloma patients, care­givers, and health care professionals have been asking a number of important questions about Farydak. This article compiles many of those questions and provides answers to them.

The information in this article is based primarily on the official, FDA-approved prescribing information for Farydak. …

Tags: , , , ,
Read the full story »
[ by | Feb 23, 2015 3:30 pm | 14 Comments ]
FDA Approves Farydak (Panobinostat) For The Treatment Of Relapsed Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has approved panobinostat, which will be marketed under the brand name Farydak, for the treatment of relapsed and refractory multiple myeloma.

Specifically, Farydak has been approved for use in combination with Velcade (bortezomib) and dexamethasone (Decadron) in patients with multiple myeloma who have received at least two prior standard therapies.

The two prior therapies must include Velcade and at least one treatment from the immunomodulatory class of drugs, …

Tags: , , , ,
Read the full story »